{"id":172461,"date":"2025-11-18T03:46:26","date_gmt":"2025-11-18T08:46:26","guid":{"rendered":"https:\/\/44.250.171.167\/?p=172461"},"modified":"2025-11-18T03:46:26","modified_gmt":"2025-11-18T08:46:26","slug":"concord-biotech-q2-fy26-earnings-results","status":"publish","type":"post","link":"https:\/\/alphastreet.com\/india\/concord-biotech-q2-fy26-earnings-results\/","title":{"rendered":"Concord Biotech\u00a0Q2 FY26 Earnings Results"},"content":{"rendered":"<p>Concord Biotech Limited, an India-based R&amp;D-driven biopharma company specializing in fermentation-based APIs for immunosuppressants and oncology, reported a decline in financial performance for Q2FY26.<\/p>\n<h2>Financial Highlights:<\/h2>\n<ul>\n<li>Revenues declined 20.32% year-on-year to \u20b9247 crore from \u20b9310 crore.<\/li>\n<li>Total expenses decreased 6.35% to \u20b9177 crore from \u20b9189 crore.<\/li>\n<li>Consolidated net <a href=\"https:\/\/www.bseindia.com\/xml-data\/corpfiling\/AttachHis\/ae698aba-dfb5-445e-a99f-f63c2f3bc44a.pdf\" target=\"_blank\" rel=\"noopener\">profit<\/a> dropped 34.38% to \u20b963 crore from \u20b996 crore.<\/li>\n<li>Earnings per share fell 33.55% to \u20b96.08 from \u20b99.15.<\/li>\n<\/ul>\n<p>The profit decline was primarily due to lower revenues despite cost reductions. The company is focusing on strengthening its product pipeline and operational efficiencies.<\/p>\n<h2>Outlook:<\/h2>\n<p>Concord Biotech aims to enhance R&amp;D, expand its product portfolio, and improve manufacturing capabilities to drive future growth. It is well-positioned to benefit from growing demand in immunosuppressants and oncology segments.<\/p>\n<p>Explore the company\u2019s past earnings and latest concall transcripts, <a href=\"https:\/\/44.250.171.167\/symbol\/concordbio\/\">click here<\/a> to visit the AlphaStreet India News Channel.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"aligncenter size-full wp-image-172462\" src=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/C-4.png\" alt=\"Q2 FY26\" width=\"1489\" height=\"1817\" srcset=\"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/C-4.png 1489w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/C-4-246x300.png 246w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/C-4-839x1024.png 839w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/C-4-768x937.png 768w, https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/C-4-1259x1536.png 1259w\" sizes=\"auto, (max-width: 1489px) 100vw, 1489px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Concord Biotech Limited, an India-based R&amp;D-driven biopharma company specializing in fermentation-based APIs for immunosuppressants and oncology, reported a decline in financial performance for Q2FY26. Financial Highlights: Revenues declined 20.32% year-on-year to \u20b9247 crore from \u20b9310 crore. Total expenses decreased 6.35% to \u20b9177 crore from \u20b9189 crore. Consolidated net profit dropped 34.38% to \u20b963 crore from [&hellip;]<\/p>\n","protected":false},"author":1932,"featured_media":172462,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"jetpack_post_was_ever_published":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[105,392],"tags":[10304,11333],"class_list":["post-172461","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-infographics","category-earnings","tag-api","tag-oncology"],"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/C-4.png","jetpack_likes_enabled":false,"jetpack-related-posts":[{"id":171070,"url":"https:\/\/alphastreet.com\/india\/concord-biotech-q1-fy26-earnings-results\/","url_meta":{"origin":172461,"position":0},"title":"Concord Biotech Q1 FY26 Earnings Results","author":"Divyansh_Kasana","date":"September 9, 2025","format":false,"excerpt":"Concord Biotech Limited, incorporated in 1984, is an India-based R&D-driven biopharma company specializing in the manufacture of fermentation-based active pharmaceutical ingredients (APIs) primarily for immunosuppressants and oncology. Presenting below its Q1 FY26 Earnings Results. Q1 FY26 Earnings Results: Revenue: \u20b9204 crore, down 5.56% year-on-year YoY from \u20b9216 crore Total Expenses:\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"CONCORDBIO Q1 FY26 Earnings Results","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/09\/CONCOR.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166037,"url":"https:\/\/alphastreet.com\/india\/concord-biotech-ltd-q2fy25-19-rise-in-profits\/","url_meta":{"origin":172461,"position":1},"title":"Concord Biotech Ltd Q2FY25; 19% rise in Profits","author":"Divyansh_Kasana","date":"December 12, 2024","format":false,"excerpt":"Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. Financial Results: Concord Biotech Ltd reported Revenues for Q2FY25 of \u20b9310.00 Crores up from \u20b9262.00 Crore year on year, a rise of 18.32%. Total Expenses for Q2FY25 of \u20b9189.00\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HT-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HT-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HT-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HT-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HT-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2024\/12\/HT-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":166453,"url":"https:\/\/alphastreet.com\/india\/concord-biotech-ltd-q3fy25-33-rise-in-profits\/","url_meta":{"origin":172461,"position":2},"title":"Concord Biotech Ltd Q3FY25; 33% rise in Profits","author":"Divyansh_Kasana","date":"January 21, 2025","format":false,"excerpt":"Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. Financial Results: Concord Biotech Ltd reported Revenues for Q3FY25 of \u20b9237.00 Crores up from \u20b9241.00 Crore year on year, a rise of 30.22%. Total Expenses for Q3FY25 of \u20b9141.00\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/JJ-2.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/JJ-2.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/JJ-2.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/JJ-2.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/JJ-2.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/01\/JJ-2.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":168963,"url":"https:\/\/alphastreet.com\/india\/concord-biotech-ltd-q4fy25-47-rise-in-profits\/","url_meta":{"origin":172461,"position":3},"title":"Concord Biotech Ltd Q4FY25; 47% rise in Profits","author":"Divyansh_Kasana","date":"July 1, 2025","format":false,"excerpt":"Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company and manufacturer of fermentation-based APIs across immunosuppressants and oncology. Financial Results: Concord Biotech Ltd reported Revenues for Q4FY25 of \u20b9430.00 Crores up from \u20b9319.00 Crore year on year, a rise of 34.8%. Total Expenses for Q4FY25 of \u20b9256.00\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/07\/O.png?resize=1400%2C800&ssl=1 4x"},"classes":[]},{"id":144681,"url":"https:\/\/alphastreet.com\/india\/rossari-biotech-ltd-q4fy23-results-out-net-profit-soars-by-21\/","url_meta":{"origin":172461,"position":4},"title":"Rossari Biotech Ltd Q4FY23 results out, Net Profit soars by 21%","author":"Chirag Gupta","date":"May 1, 2023","format":false,"excerpt":"Started in 2003, Rossari Biotech is among the largest manufacturers of textile specialty chemicals in India. Their 3 main product categories are:- Home, personal care & performance chemicals, Textile specialty chemical and Animal health and nutrition. The company has two R&D facilities, one at Silvassa manufacturing facility and a research\u2026","rel":"","context":"In &quot;Earnings&quot;","block_context":{"text":"Earnings","link":"https:\/\/alphastreet.com\/india\/category\/earnings\/"},"img":{"alt_text":"","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2021\/11\/Earnings-Coverage.jpg?resize=525%2C300&ssl=1 1.5x"},"classes":[]},{"id":172499,"url":"https:\/\/alphastreet.com\/india\/deepak-nitrite-q2-fy26-earnings-results\/","url_meta":{"origin":172461,"position":5},"title":"Deepak Nitrite Q2 FY26 Earnings Results","author":"Divyansh_Kasana","date":"November 19, 2025","format":false,"excerpt":"Deepak Nitrite Ltd, manufacturing Basic Intermediates, Fine & Specialty Chemicals, Performance Products, and Phenolics, reported a decline in Q2FY26 profits due to lower revenues. Financial Highlights: Revenues fell 6.4% year-on-year to \u20b91,902 crore from \u20b92,032 crore. Total expenses decreased 1.62% to \u20b91,759 crore from \u20b91,788 crore. Consolidated net profit dropped\u2026","rel":"","context":"In &quot;AlphaGraphs&quot;","block_context":{"text":"AlphaGraphs","link":"https:\/\/alphastreet.com\/india\/category\/infographics\/"},"img":{"alt_text":"Q2 FY26","src":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/NTR.png?resize=350%2C200&ssl=1","width":350,"height":200,"srcset":"https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/NTR.png?resize=350%2C200&ssl=1 1x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/NTR.png?resize=525%2C300&ssl=1 1.5x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/NTR.png?resize=700%2C400&ssl=1 2x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/NTR.png?resize=1050%2C600&ssl=1 3x, https:\/\/i0.wp.com\/alphastreet.com\/india\/wp-content\/uploads\/2025\/11\/NTR.png?resize=1400%2C800&ssl=1 4x"},"classes":[]}],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172461","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/users\/1932"}],"replies":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/comments?post=172461"}],"version-history":[{"count":0,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/posts\/172461\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media\/172462"}],"wp:attachment":[{"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/media?parent=172461"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/categories?post=172461"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/alphastreet.com\/india\/wp-json\/wp\/v2\/tags?post=172461"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}